tradingkey.logo

Neuronetics Inc

STIM
查看详细走势图
1.560USD
+0.140+9.86%
收盘 02/06, 16:00美东报价延迟15分钟
106.77M总市值
亏损市盈率 TTM

Neuronetics Inc

1.560
+0.140+9.86%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+9.86%

5天

-25.36%

1月

-20.41%

6月

-62.23%

今年开始到现在

+13.04%

1年

-49.19%

查看详细走势图

TradingKey Neuronetics Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Neuronetics Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名89/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.50。中期看,股价处于下降通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Neuronetics Inc评分

相关信息

行业排名
89 / 205
全市场排名
239 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Neuronetics Inc亮点

亮点风险
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
业绩增长期
公司处于发展阶段,最新年度总收入74.89M美元
利润高增长
公司净利润处于行业前列,最新年度总收入74.89M美元
估值合理
公司最新PE估值-1.88,处于3年历史合理位
机构减仓
最新机构持股42.40M股,环比减少26.69%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值13.74K
活跃度增加
近期活跃度增加,过去20天平均换手率0.95

分析师目标

根据 3 位分析师
买入
评级
6.500
目标均价
+316.67%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Neuronetics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Neuronetics Inc简介

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
公司代码STIM
公司Neuronetics Inc
CEOMr. Keith J. Sullivan
网址https://neurostar.com/neuronetics/
KeyAI